TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma.
Camilo JimenezJunsheng MaAlejandro Roman GonzalezJeena VargheseMiao ZhangNancy PerrierMouhammed Amir HabraPaul GrahamSteven G WaguespackPublished in: The Journal of clinical endocrinology and metabolism (2022)
OS rates correlated with the recently developed AJCC TNM staging and was not worse in hereditary disease. Stage IV disease exhibited a significantly shorter OS compared with stages I-III. Future staging systems could be adjusted to better separate stages I and II.
Keyphrases